ABSTRACT
BACKGROUND: Nipah virus is a highly virulent zoonotic pathogen that can be transmitted between humans. Understanding the dynamics of person-to-person transmission is key to designing effective interventions. METHODS: We used data from all Nipah virus cases identified during outbreak investigations in Bangladesh from April 2001 through April 2014 to investigate case-patient characteristics associated with onward transmission and factors associated with the risk of infection among patient contacts. RESULTS: Of 248 Nipah virus cases identified, 82 were caused by person-to-person transmission, corresponding to a reproduction number (i.e., the average number of secondary cases per case patient) of 0.33 (95% confidence interval [CI], 0.19 to 0.59). The predicted reproduction number increased with the case patient's age and was highest among patients 45 years of age or older who had difficulty breathing (1.1; 95% CI, 0.4 to 3.2). Case patients who did not have difficulty breathing infected 0.05 times as many contacts (95% CI, 0.01 to 0.3) as other case patients did. Serologic testing of 1863 asymptomatic contacts revealed no infections. Spouses of case patients were more often infected (8 of 56 [14%]) than other close family members (7 of 547 [1.3%]) or other contacts (18 of 1996 [0.9%]). The risk of infection increased with increased duration of exposure of the contacts (adjusted odds ratio for exposure of >48 hours vs. ≤1 hour, 13; 95% CI, 2.6 to 62) and with exposure to body fluids (adjusted odds ratio, 4.3; 95% CI, 1.6 to 11). CONCLUSIONS: Increasing age and respiratory symptoms were indicators of infectivity of Nipah virus. Interventions to control person-to-person transmission should aim to reduce exposure to body fluids. (Funded by the National Institutes of Health and others.).
Subject(s)
Henipavirus Infections/transmission , Nipah Virus , Adolescent , Adult , Age Factors , Animals , Bangladesh/epidemiology , Body Fluids/virology , Child , Contact Tracing , Disease Transmission, Infectious/prevention & control , Female , Henipavirus Infections/epidemiology , Henipavirus Infections/prevention & control , Humans , Male , Middle Aged , Risk Factors , Young Adult , Zoonoses/transmissionABSTRACT
In 2011, ticks were collected from livestock following an outbreak of Crimean Congo hemorrhagic fever (CCHF) in Gujarat state, India. CCHF-negative Hyalomma anatolicum tick pools were passaged for virus isolation, and two virus isolates were obtained, designated Karyana virus (KARYV) and Kundal virus (KUNDV), respectively. Traditional reverse transcription-PCR (RT-PCR) identification of known viruses was unsuccessful, but a next-generation sequencing (NGS) approach identified KARYV and KUNDV as viruses in the Reoviridae family, Orbivirus and Coltivirus genera, respectively. Viral genomes were de novo assembled, yielding 10 complete segments of KARYV and 12 nearly complete segments of KUNDV. The VP1 gene of KARYV shared a most recent common ancestor with Wad Medani virus (WMV), strain Ar495, and based on nucleotide identity we demonstrate that it is a novel WMV strain. The VP1 segment of KUNDV shares a common ancestor with Colorado tick fever virus, Eyach virus, Tai Forest reovirus, and Tarumizu tick virus from the Coltivirus genus. Based on VP1, VP6, VP7, and VP12 nucleotide and amino acid identities, KUNDV is proposed to be a new species of Coltivirus Electron microscopy supported the classification of KARYV and KUNDV as reoviruses and identified replication morphology consistent with other orbi- and coltiviruses. The identification of novel tick-borne viruses carried by the CCHF vector is an important step in the characterization of their potential role in human and animal pathogenesis.IMPORTANCE Ticks and mosquitoes, as well Culicoides, can transmit viruses in the Reoviridae family. With the help of next-generation sequencing (NGS), previously unreported reoviruses such as equine encephalosis virus, Wad Medani virus (WMV), Kammavanpettai virus (KVPTV), and, with this report, KARYV and KUNDV have been discovered and characterized in India. The isolation of KUNDV and KARYV from Hyalomma anatolicum, which is a known vector for zoonotic pathogens, such as Crimean Congo hemorrhagic fever virus, Babesia, Theileria, and Anaplasma species, identifies arboviruses with the potential to transmit to humans. Characterization of KUNDV and KARYV isolated from Hyalomma ticks is critical for the development of specific serological and molecular assays that can be used to determine the association of these viruses with disease in humans and livestock.
Subject(s)
Coltivirus/classification , Coltivirus/isolation & purification , Hemorrhagic Fever Virus, Crimean-Congo/isolation & purification , Hemorrhagic Fever, Crimean/complications , Orbivirus/classification , Orbivirus/isolation & purification , Phylogeny , Ticks/virology , Animals , Chlorocebus aethiops , Coltivirus/genetics , Culicidae/virology , Genome, Viral , Hemorrhagic Fever Virus, Crimean-Congo/classification , Hemorrhagic Fever Virus, Crimean-Congo/genetics , Hemorrhagic Fever, Crimean/epidemiology , Hemorrhagic Fever, Crimean/virology , High-Throughput Nucleotide Sequencing , Humans , India , Mosquito Vectors/virology , Orbivirus/genetics , Reoviridae/classification , Reoviridae/genetics , Reoviridae/isolation & purification , Reoviridae/ultrastructure , Vero Cells , Viral Plaque Assay , Viral Proteins/geneticsABSTRACT
We detected Zika virus RNA in rectal swab samples from 10 patients by using real-time reverse transcription PCR, and we isolated the virus from 1 patient. The longest interval from symptom onset to detection was 14 days. These findings are applicable to diagnosis and infection prevention recommendations.
Subject(s)
Rectum/virology , Zika Virus Infection/virology , Zika Virus/isolation & purification , Adult , Female , Humans , Male , RNA, Viral/isolation & purification , Real-Time Polymerase Chain Reaction , Young Adult , Zika Virus/genetics , Zika Virus Infection/blood , Zika Virus Infection/urineABSTRACT
Nipah virus (NiV) has been transmitted from patient to caregivers in Bangladesh presumably through oral secretions. We aimed to detect whether NiV-infected patients contaminate hospital surfaces with the virus. During December 2013-April 2014, we collected 1 swab sample from 5 surfaces near NiV-infected patients and tested surface and oral swab samples by real-time reverse transcription PCR for NiV RNA. We identified 16 Nipah patients; 12 cases were laboratory-confirmed and 4 probable. Of the 12 laboratory-confirmed cases, 10 showed NiV RNA in oral swab specimens. We obtained surface swab samples for 6 Nipah patients; 5 had evidence of NiV RNA on >1 surface: 4 patients contaminated towels, 3 bed sheets, and 1 the bed rail. Patients with NiV RNA in oral swab samples were significantly more likely than other Nipah patients to die. To reduce the risk for fomite transmission of NiV, infection control should target hospital surfaces.
Subject(s)
Equipment Contamination , Henipavirus Infections/epidemiology , Henipavirus Infections/virology , Hospitals , Nipah Virus/isolation & purification , Bangladesh/epidemiology , Bedding and Linens/virology , Beds/virology , Disease Outbreaks , Fomites , Henipavirus Infections/mortality , Humans , Infection Control/methods , Mouth/virology , RNA, Viral/isolation & purificationABSTRACT
We describe a strain of Lassa virus representing a putative new lineage that was isolated from a cluster of human infections with an epidemiologic link to Togo. This finding extends the known range of Lassa virus to Togo.
Subject(s)
Lassa Fever/epidemiology , Lassa Fever/virology , Lassa virus/classification , Animals , Chlorocebus aethiops , Genes, Viral , History, 21st Century , Humans , Lassa Fever/history , Phylogeny , Togo/epidemiology , Vero CellsABSTRACT
Among the survivors of Ebola virus disease (EVD), complications that include uveitis can develop during convalescence, although the incidence and pathogenesis of EVD-associated uveitis are unknown. We describe a patient who recovered from EVD and was subsequently found to have severe unilateral uveitis during convalescence. Viable Zaire ebolavirus (EBOV) was detected in aqueous humor 14 weeks after the onset of EVD and 9 weeks after the clearance of viremia.
Subject(s)
Aqueous Humor/virology , Ebolavirus/isolation & purification , Hemorrhagic Fever, Ebola/complications , Panuveitis/virology , Vision Disorders/virology , Adult , Convalescence , Fundus Oculi , Humans , MaleABSTRACT
A suspected case of sexual transmission from a male survivor of Ebola virus disease (EVD) to his female partner (the patient in this report) occurred in Liberia in March 2015. Ebola virus (EBOV) genomes assembled from blood samples from the patient and a semen sample from the survivor were consistent with direct transmission. The genomes shared three substitutions that were absent from all other Western African EBOV sequences and that were distinct from the last documented transmission chain in Liberia before this case. Combined with epidemiologic data, the genomic analysis provides evidence of sexual transmission of EBOV and evidence of the persistence of infective EBOV in semen for 179 days or more after the onset of EVD. (Funded by the Defense Threat Reduction Agency and others.).
Subject(s)
Ebolavirus/genetics , Hemorrhagic Fever, Ebola/transmission , Semen/virology , Adult , Coitus , Ebolavirus/isolation & purification , Female , Genome, Viral , Hemorrhagic Fever, Ebola/virology , Humans , Liberia , Male , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction , Unsafe SexABSTRACT
Four Ebola patients received care at Emory University Hospital, presenting a unique opportunity to examine the cellular immune responses during acute Ebola virus infection. We found striking activation of both B and T cells in all four patients. Plasmablast frequencies were 10-50% of B cells, compared with less than 1% in healthy individuals. Many of these proliferating plasmablasts were IgG-positive, and this finding coincided with the presence of Ebola virus-specific IgG in the serum. Activated CD4 T cells ranged from 5 to 30%, compared with 1-2% in healthy controls. The most pronounced responses were seen in CD8 T cells, with over 50% of the CD8 T cells expressing markers of activation and proliferation. Taken together, these results suggest that all four patients developed robust immune responses during the acute phase of Ebola virus infection, a finding that would not have been predicted based on our current assumptions about the highly immunosuppressive nature of Ebola virus. Also, quite surprisingly, we found sustained immune activation after the virus was cleared from the plasma, observed most strikingly in the persistence of activated CD8 T cells, even 1 mo after the patients' discharge from the hospital. These results suggest continued antigen stimulation after resolution of the disease. From these convalescent time points, we identified CD4 and CD8 T-cell responses to several Ebola virus proteins, most notably the viral nucleoprotein. Knowledge of the viral proteins targeted by T cells during natural infection should be useful in designing vaccines against Ebola virus.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Ebolavirus/immunology , Hemorrhagic Fever, Ebola/immunology , Immunity, Cellular/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Ebolavirus/metabolism , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Hemorrhagic Fever, Ebola/blood , Hemorrhagic Fever, Ebola/virology , Humans , Immunity, Humoral/immunology , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunophenotyping , Interferon-gamma/immunology , Interferon-gamma/metabolism , Lymphocyte Activation/immunology , Precursor Cells, B-Lymphoid/immunology , Precursor Cells, B-Lymphoid/metabolism , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , Viral Proteins/immunology , Viral Proteins/metabolismABSTRACT
Here we describe clinicopathologic features of Ebola virus disease in pregnancy. One woman infected with Sudan virus in Gulu, Uganda, in 2000 had a stillbirth and survived, and another woman infected with Bundibugyo virus had a live birth with maternal and infant death in Isiro, the Democratic Republic of the Congo in 2012. Ebolavirus antigen was seen in the syncytiotrophoblast and placental maternal mononuclear cells by immunohistochemical analysis, and no antigen was seen in fetal placental stromal cells or fetal organs. In the Gulu case, ebolavirus antigen localized to malarial parasite pigment-laden macrophages. These data suggest that trophoblast infection may be a mechanism of transplacental ebolavirus transmission.
Subject(s)
Ebolavirus/isolation & purification , Hemorrhagic Fever, Ebola/pathology , Hemorrhagic Fever, Ebola/virology , Pregnancy Complications, Infectious/pathology , Pregnancy Complications, Infectious/virology , Adult , Antibodies, Viral/blood , Antigens, Viral/immunology , Antigens, Viral/isolation & purification , Democratic Republic of the Congo , Ebolavirus/chemistry , Ebolavirus/genetics , Ebolavirus/immunology , Female , Hemorrhagic Fever, Ebola/immunology , Hemorrhagic Fever, Ebola/transmission , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunohistochemistry , Macrophages/parasitology , Macrophages/ultrastructure , Macrophages/virology , Malaria/complications , Malaria/immunology , Malaria/virology , Microscopy, Electron, Transmission , Placenta/ultrastructure , Placenta/virology , Polymerase Chain Reaction , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/parasitology , Stillbirth , Stromal Cells/ultrastructure , Stromal Cells/virology , Trophoblasts/parasitology , Trophoblasts/ultrastructure , Trophoblasts/virologyABSTRACT
Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged detectable virus RNA in blood and semen, suggesting that the possibility of sexual transmission of Lassa virus should be considered.
Subject(s)
Amides/therapeutic use , Antiviral Agents/therapeutic use , Lassa Fever , Pyrazines/therapeutic use , Ribavirin/therapeutic use , Adult , Humans , Lassa Fever/drug therapy , Lassa Fever/physiopathology , Lassa Fever/virology , Lassa virus/genetics , Male , Polymerase Chain Reaction , RNA, Viral/analysis , RNA, Viral/genetics , TogoABSTRACT
In September 2014, a single fatal case of Marburg virus was identified in a healthcare worker in Kampala, Uganda. The source of infection was not identified, and no secondary cases were identified. We describe the rapid identification, laboratory diagnosis, and case investigation of the third Marburg virus outbreak in Uganda.
Subject(s)
Disease Outbreaks , Marburg Virus Disease/epidemiology , Marburg Virus Disease/prevention & control , Marburgvirus/genetics , Phylogeny , Adult , Animals , Chiroptera/virology , Disease Reservoirs/virology , Fatal Outcome , Humans , Male , Marburgvirus/classification , Marburgvirus/isolation & purification , Personal Protective Equipment/statistics & numerical data , Uganda/epidemiologyABSTRACT
West Africa is currently experiencing the largest outbreak of Ebola virus disease (EVD) in history. Two patients with EVD were transferred from Liberia to our hospital in the United States for ongoing care. Malaria had also been diagnosed in one patient, who was treated for it early in the course of EVD. The two patients had substantial intravascular volume depletion and marked electrolyte abnormalities. We undertook aggressive supportive measures of hydration (typically, 3 to 5 liters of intravenous fluids per day early in the course of care) and electrolyte correction. As the patients' condition improved clinically, there was a concomitant decline in the amount of virus detected in plasma.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Viral/therapeutic use , Drugs, Investigational/therapeutic use , Ebolavirus/immunology , Hemorrhagic Fever, Ebola/therapy , Adult , Disease Outbreaks , Female , Hemorrhagic Fever, Ebola/drug therapy , Hemorrhagic Fever, Ebola/epidemiology , Humans , Liberia , Male , Middle Aged , United StatesABSTRACT
Despite careful donor screening, unexpected donor-derived infections continue to occur in organ transplant recipients (OTRs). Lymphocytic choriomeningitis virus (LCMV) is one such transplant-transmitted infection that in previous reports has resulted in a high mortality among the affected OTRs. We report a LCMV case cluster that occurred 3 weeks post-transplant in three OTRs who received allografts from a common organ donor in March 2013. Following confirmation of LCMV infection at Centers for Disease Control and Prevention, immunosuppression was promptly reduced and ribavirin and/or intravenous immunoglobulin therapy were initiated in OTRs. The liver recipient died, but right kidney recipients survived without significant sequelae and left kidney recipient survived acute LCMV infection with residual mental status deficit. Our series highlights how early recognition led to prompt therapeutic intervention, which may have contributed to more favorable outcome in the kidney transplant recipients.
Subject(s)
Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Lymphocytic Choriomeningitis/diagnosis , Lymphocytic choriomeningitis virus/isolation & purification , Aged , Donor Selection , Early Medical Intervention , Fatal Outcome , Female , Humans , Immunosuppression Therapy , Kidney/pathology , Kidney/virology , Liver/pathology , Liver/virology , Lymphocytic Choriomeningitis/etiology , Lymphocytic Choriomeningitis/pathology , Lymphocytic choriomeningitis virus/genetics , Male , Middle Aged , Tissue Donors , Transplant Recipients , Transplantation, HomologousABSTRACT
BACKGROUND: Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics. METHODS: To investigate whether treatment selected for Ebola virus (EBOV) mutations conferring resistance, viral sequencing was performed on RNA extracted from clinical blood specimens from patients with EVD following treatment, and putative viral targets were analyzed. RESULTS: We observed no major or minor EBOV mutations within regions targeted by therapeutics. CONCLUSIONS: This small subset of patients and clinical specimens suggests that evolution of resistance is not a direct consequence of antiviral treatment. As EVD antiviral treatments are introduced into wider use, it is essential that continuous viral full-genome surveillance is performed, to monitor for the emergence of escape mutations.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antiviral Agents/therapeutic use , Ebolavirus/drug effects , Genome, Viral/genetics , Hemorrhagic Fever, Ebola/drug therapy , RNA, Small Interfering/therapeutic use , Convalescence , Drug Resistance, Viral , Ebolavirus/genetics , Ebolavirus/immunology , Evolution, Molecular , Hemorrhagic Fever, Ebola/immunology , Hemorrhagic Fever, Ebola/virology , High-Throughput Nucleotide Sequencing , Humans , Molecular Epidemiology , Mutation , Plasma , Sequence Analysis, DNAABSTRACT
West Africa experienced the first epidemic of Ebola virus infection, with by far the greatest number of cases in Guinea, Sierra Leone, and Liberia. The unprecedented epidemic triggered an unparalleled response, including the deployment of multiple Ebola treatment units and mobile/field diagnostic laboratories. The National Institute of Allergy and Infectious Diseases and the Centers for Disease Control and Prevention deployed a joint laboratory to Monrovia, Liberia, in August 2014 to support the newly founded Ebola treatment unit at the Eternal Love Winning Africa (ELWA) campus. The laboratory operated initially out of a tent structure but quickly moved into a fixed-wall building owing to severe weather conditions, the need for increased security, and the high sample volume. Until May 2015, when the laboratory closed, the site handled close to 6000 clinical specimens for Ebola virus diagnosis and supported the medical staff in case patient management. Laboratory operation and safety, as well as Ebola virus diagnostic assays, are described and discussed; in addition, lessons learned for future deployments are reviewed.
Subject(s)
Clinical Laboratory Services/organization & administration , Ebolavirus/isolation & purification , Epidemics/prevention & control , Hemorrhagic Fever, Ebola/epidemiology , Africa, Western/epidemiology , Centers for Disease Control and Prevention, U.S. , Female , Guinea/epidemiology , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/transmission , Hemorrhagic Fever, Ebola/virology , Humans , International Cooperation , Liberia/epidemiology , Male , National Institute of Allergy and Infectious Diseases (U.S.) , Safety , Sierra Leone/epidemiology , United StatesABSTRACT
We investigated the duration of Ebola virus (EBOV) RNA and infectious EBOV in semen specimens of 5 Ebola virus disease (EVD) survivors. EBOV RNA and infectious EBOV was detected by real-time RT-PCR and virus culture out to 290 days and 70 days, respectively, after EVD onset.
Subject(s)
Ebolavirus/isolation & purification , Hemorrhagic Fever, Ebola/virology , Semen/virology , Adult , Cohort Studies , Ebolavirus/pathogenicity , Humans , Male , SurvivorsABSTRACT
From September 2014 to April 2015, 6 persons who had occupational exposures to Zaire ebolavirus in West Africa received investigational agent rVSV-ZEBOV or TKM-100802 for postexposure prophylaxis and were monitored in the United States. All patients experienced self-limited symptoms after postexposure prophylaxis; none developed Ebola virus disease.
Subject(s)
Ebolavirus/physiology , Hemorrhagic Fever, Ebola/prevention & control , Occupational Exposure , Adult , Africa, Western , Female , Hemorrhagic Fever, Ebola/diagnosis , Hemorrhagic Fever, Ebola/virology , Humans , Male , Middle Aged , Post-Exposure Prophylaxis , Retrospective Studies , United StatesABSTRACT
Many of the survivors of the 2014-2015 epidemic of Ebola virus disease (EVD) in western Africa were women of childbearing age. Limited clinical and laboratory data exist that describe these women's pregnancies and outcomes. We report the case of an EVD survivor who became pregnant and delivered her child in the United States, and we discuss implications of this case for infection control practices in obstetric services. Hospitals in the United States must be prepared to care for EVD survivors.
Subject(s)
Labor, Obstetric , Parturition , Pregnancy Complications, Infectious , Adult , Africa, Western/epidemiology , Female , Hospitals , Humans , Infection Control , Pregnancy , United StatesABSTRACT
We report a case of probable Zaire Ebola virus-related ophthalmologic complications in a physician from the United States who contracted Ebola virus disease in Liberia. Uveitis, immune activation, and nonspecific increase in antibody titers developed during convalescence. This case highlights immune phenomena that could complicate management of Ebola virus disease-related uveitis during convalescence.
Subject(s)
Ebolavirus , Hemorrhagic Fever, Ebola/complications , Hemorrhagic Fever, Ebola/virology , Uveitis/diagnosis , Uveitis/etiology , Ebolavirus/genetics , Hemorrhagic Fever, Ebola/diagnosis , Humans , Liberia , Male , Tomography, Optical Coherence , Uveitis/drug therapyABSTRACT
Nipah virus (NiV) is a paramyxovirus, and Pteropus spp. bats are the natural reservoir. From December 2010 through March 2014, hospital-based encephalitis surveillance in Bangladesh identified 18 clusters of NiV infection. The source of infection for case-patients in 3 clusters in 2 districts was unknown. A team of epidemiologists and anthropologists investigated these 3 clusters comprising 14 case-patients, 8 of whom died. Among the 14 case-patients, 8 drank fermented date palm sap (tari) regularly before their illness, and 6 provided care to a person infected with NiV. The process of preparing date palm trees for tari production was similar to the process of collecting date palm sap for fresh consumption. Bat excreta was reportedly found inside pots used to make tari. These findings suggest that drinking tari is a potential pathway of NiV transmission. Interventions that prevent bat access to date palm sap might prevent tari-associated NiV infection.